Device Trial Radar · NCT07575568
Revascularization With Modification Using Definitive IVL and Serration Remodeling for Optimal Lumen
Last checked: Nov 20, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 2026
Primary completion
Aug 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- Cagent Vascular LLCNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Clinical Accelerator; Australian Healthcare Solutions; Yale Cardiovascular Research Group
- First posted
- May 8, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this first-in-human study is to assess the safety and effectiveness of the Serranator Sonic Intravascular Lithotripsy (IVL) System™ for the treatment of peripheral artery disease.
Conditions
- Peripheral Artery Disease
Interventions
Serranator Sonic Intravascular Lithotripsy (IVL) SystemDevice
Serration remodeling balloon angioplasty with Intravascular Lithotripsy of the superficial femoral and popliteal arteries for Cohort A: Above-the-Knee; treatment of the infrapopliteal and inframalleolar arteries for Cohort B: Below-the-Knee.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Safety: Major Adverse EventsTime frame: 30 Days
- Primary Effectiveness: Procedural SuccessTime frame: Procedure
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.